Erythropoietin for traumatic brain injury

JAMA - Journal of the American Medical Association

Volumn 312, Issue 18, 2014, Pages 1928-1929

  Nichol, Alistair ^a   Little, Lorraine ^b   French, Craig ^c  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b MONASH UNIVERSITY   (Australia)

^c WESTERN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; LONG TERM SURVIVAL; OUTCOME ASSESSMENT; TRAUMATIC BRAIN INJURY; ANEMIA; BRAIN INJURY; COMPLICATION; ERYTHROCYTE TRANSFUSION; FEMALE; MALE;

ANEMIA; BRAIN INJURIES; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE;

EID: 84918784908     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.12738     Document Type: Letter

References (2)

1. Robertson CS, Hannay HJ, Yamal J-M, et al; Epo Severe TBI Trial Investigators. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA. 2014;312(1):36-47.
2. Corwin HL, Gettinger A, Fabian TC, et al; EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357(10):965-976.